New combo therapy offers hope for Drug-Resistant digestive cancer
Disease control
Recruiting now
This study tests whether combining two drugs—regorafenib and envafolimab—can help people with a rare type of stomach or intestinal cancer (GIST) that has stopped responding to standard treatments. About 100 adults with a specific gene mutation (KIT exon 17) will be randomly assig…
Phase: PHASE2 • Sponsor: Jian Li • Aim: Disease control
Last updated May 14, 2026 12:03 UTC